

NANOGEN INC  
Form 8-K  
November 29, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 23, 2004**

---

**NANOGEN, INC.**

(Exact name of registrant specified in its charter)

---

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-23541**  
(Commission File Number)

**33-0489621**  
(I.R.S. Employer

Identification No.)

**10398 Pacific Center Court, San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone, including area code: (858) 410-4600**

## Edgar Filing: NANOGEN INC - Form 8-K

(Former name and former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.04 Temporary Suspension of Trading Under Registrant's Employee Benefit Plan.**

Effective December 27, 2004 Nanogen, Inc. (the Company) is changing vendors for the administration of the Company's 401(k) Profit Sharing Plan (the Plan). To facilitate this change, there will be a blackout period for all Plan transactions. Specifically, during the blackout period Plan participants will be unable to direct or diversify investments in their Plan account, obtain a loan from the Plan or obtain a distribution from the Plan. In addition, executive officers and directors of the Company will be restricted from effecting certain transactions in Company common stock prohibited by Section 306 of the Sarbanes-Oxley Act of 2002 and Rule 101 of Regulation BTR.

On November 24, 2004 Nanogen, Inc. (the Company) sent a notice to directors and executive officers of the Company informing them that a Plan blackout period will begin on December 27, 2004 and is expected to continue until approximately February 12, 2005. The Company provided the notice to its directors and executive officers in accordance with Section 306(a) of the Sarbanes-Oxley Act of 2002 and Rule 104 of Regulation BTR. The Company also has timely notified participants in the Plan of the blackout period.

For further information regarding the blackout period, please contact Larry Respass at Nanogen, Inc., 10398 Pacific Center Court, San Diego, California 92121 or (858) 410-4600.

The Company received the notice required by Section 101(i)(2)(E) of the Employment Retirement Income Security Act of 1974 on November 23, 2004.

Edgar Filing: NANOGEN INC - Form 8-K

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NANOGEN, INC.**

Date: November 29, 2004

By:           /s/ Nicholas J. Venuto          

Name: Nicholas J. Venuto  
Title: Senior Director, Finance